inclusion criteria: the written informed consent of the subject for participation in the study; men and women over the age of 60 years inclusive; negative result of research on hiv, hepatitis, syphilis; negative test result for the presence of igm and igg antibodies to sars cov2 by enzyme immunoassay; negative test result for covid-2019, determined by pcr at the screening session; the absence of a history covid-2019; no contact of the study subject with covid-2019 patients for at least 14 days prior to inclusion in the study (according to the study participant); consent to use effective methods of contraception during the entire period of participation in the study; a negative test for the presence of narcotic and psychoactive agents in urine at the screening visit; a negative test for alcohol at screening visit; negative pregnancy test (performed for women with preserved reproductive potential) no history of severe postvaccinal reactions or postvaccinal complications after the use of immunobiological drugs; absence of acute infectious and/or respiratory diseases for at least 14 days prior to inclusion in the study.

inclusion criteria: the written informed consent of the subject for participation in the study; men and women over the age of 60 years inclusive; negative result of research on hiv, hepatitis, syphilis; negative test result for the presence of igm and igg antibodies to sars cov2 by enzyme immunoassay; negative test result for covid-2019, determined by pcr at the screening session; the absence of a history covid-2019; no contact of the study subject with covid-2019 patients for at least 14 days prior to inclusion in the study (according to the study participant); consent to use effective methods of contraception during the entire period of participation in the study; a negative test for the presence of narcotic and psychoactive agents in urine at the screening visit; a negative test for alcohol at screening visit; negative pregnancy test (performed for women with preserved reproductive potential) no history of severe postvaccinal reactions or postvaccinal complications after the use of immunobiological drugs; absence of acute infectious and/or respiratory diseases for at least 14 days prior to inclusion in the study.

inclusion criteria: 1. the written informed consent of the subject for participation in the study; 2. men and women over the age of 60 years inclusive; 3. negative result of research on hiv, hepatitis, syphilis; 4. negative test result for the presence of igm and igg antibodies to sars cov2 by enzyme immunoassay; 5. negative test result for covid-2019, determined by pcr at the screening session; 6. the absence of a history covid-2019; 7. no contact of the study subject with covid-2019 patients for at least 14 days prior to inclusion in the study (according to the study participant); 8. consent to use effective methods of contraception during the entire period of participation in the study; 9. a negative test for the presence of narcotic and psychoactive agents in urine at the screening visit; 10. a negative test for alcohol at screening visit; 11. negative pregnancy test (performed for women with preserved reproductive potential) 12. no history of severe postvaccinal reactions or postvaccinal complications after the use of immunobiological drugs; 13. absence of acute infectious and/or respiratory diseases for at least 14 days prior to inclusion in the study.

inclusion criteria: 1. the written informed consent of the subject for participation in the study; 2. men and women over the age of 60 years inclusive; 3. negative result of research on hiv, hepatitis, syphilis; 4. negative test result for the presence of igm and igg antibodies to sars cov2 by enzyme immunoassay; 5. negative test result for covid-2019, determined by pcr at the screening session; 6. the absence of a history covid-2019; 7. no contact of the study subject with covid-2019 patients for at least 14 days prior to inclusion in the study (according to the study participant); 8. consent to use effective methods of contraception during the entire period of participation in the study; 9. a negative test for the presence of narcotic and psychoactive agents in urine at the screening visit; 10. a negative test for alcohol at screening visit; 11. negative pregnancy test (performed for women with preserved reproductive potential) 12. no history of severe postvaccinal reactions or postvaccinal complications after the use of immunobiological drugs; 13. absence of acute infectious and/or respiratory diseases for at least 14 days prior to inclusion in the study.